Please login (Members) to view content or
(Nonmembers) this article.
5
Average: 5 (1 vote)
Online Exclusive Article

Enfortumab Vedotin: Nursing Perspectives on the Management of Adverse Events in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Amanda Pace
Blaine Brower
Dawn Conway
Dayna Leis
CJON 2021, 25(2), E1-E9 DOI: 10.1188/21.CJON.E1-E9

Background: Many patients with locally advanced or metastatic urothelial carcinoma (mUC) need additional treatment options beyond PD-1 or PD-L1 inhibitors and platinum-based chemotherapies. Enfortumab vedotin-ejfv (EV) is an antibody–drug conjugate directed at Nectin-4 that received accelerated approval for treatment of adults with locally advanced or mUC previously treated with PD-1/PD-L1 inhibitors and platinum- containing chemotherapy in the neoadjuvant/adjuvant, locally advanced, or metastatic settings.

Objectives: This article provides practical considerations and recommendations regarding common and potentially treatment-limiting adverse events that may arise with EV therapy.

Methods: The clinical data that supported the approval of EV are reviewed, and supporting safety and management considerations are provided based on the authors’ experience.

Findings: EV therapy can be optimized through patient and caregiver education, proactive patient monitoring, early identification of adverse events, and timely intervention to alleviate symptoms.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or